Emerging COVID-19 serology tests aim for neutralizing antibodies
New COVID-19 serology tests focus on the antibodies believed most likely to block viral entry
The next wave of serology tests from big diagnostic players could get closer to telling people whether they are protected from COVID-19 by homing in on the antibodies most likely to block viral entry into cells. The new entrants highlight how far industry remains from defining ideal tests for COVID-19 exposure and immunity.
FDA has granted 15 developers Emergency Use Authorization (EUA) for COVID-19 serology tests, which detect antibodies against SARS-CoV-2 in a patient’s blood, a sign that he or she has encountered the virus and mounted some degree of immune response. ...